EUVIMEDEUVIMED entdecken
MetaanalyseÜbersichtsarbeitOpen Access · CC BY-NC 4.0

MTAP immunohistochemistry as a surrogate marker of CDKN2A loss in brain tumors: A meta-analysis and literature review

Antonio Dono iD, Diego Pichardo-Rojas, Leonardo Mendoza Mora, Pavel S Pichardo-Rojas, Luis A Marin-Castañeda, Abril Carrillo, Adrian Coria Medrano, Yoshua Esquenazi iD, Leomar Y Ballester

Journal of Neuropathology & Experimental Neurology · 01.07.2025 · 84 (7) · 600-610

DOI: 10.1093/jnen/nlaf033 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Journal of Neuropathology & Experimental Neurology, online erschienen am 18.04.2025. Verfasst von Antonio Dono und 8 weiteren Autor:innen. Beteiligte Einrichtung: Vivian L. Smith Department of Neurosurgery, The University of Texas, Health Science Center at Houston, Houston, TX, United States. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Brain Neoplasms, Cyclin-Dependent Kinase Inhibitor p16, Purine-Nucleoside Phosphorylase. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Given the known relationship between CDKN2A homozygous deletion (HD) and worsened outcomes in both meningiomas and IDH-mutant astrocytomas, it is paramount to identify CDKN2A HD for accurate risk stratification of patients. Multiple array platforms can detect CDKN2A HD. However, these methods are expensive and are not readily available at every institution. To address this, we conducted a meta-analysis and literature review to evaluate 5′-methylthioadenosine phosphorylase (MTAP) expression determined by immunohistochemistry (IHC) as a surrogate of CDKN2A HD. Our study analyzed 7 cohort studies, 3 of which focused on meningiomas encompassing a total of 87 patients; and 4 studies were conducted on infiltrating glioma patients, consisting of 423 patients. Our results show that despite utilizing different MTAP IHC clones, the results among all studies showed consistently good sensitivity and specificity. The overall sensitivity and specificity of MTAP IHC as a surrogate of CDKN2A HD was excellent with 92.3% and 97.5%, respectively. These results were maintained when MTAP IHC was evaluated in distinct tumor types. MTAP IHC is a good surrogate marker for identifying CDKN2A HD in infiltrating gliomas and meningiomas. MTAP IHC implementation would allow correct integrated diagnosis for institutions that lack DNA sequencing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorBrain NeoplasmsCyclin-Dependent Kinase Inhibitor p16Purine-Nucleoside PhosphorylaseHumansGliomaImmunohistochemistryMeningioma

Stichwörter der Autor:innen

2021 WHO classificationCDKN2AMTAPastrocytomameningioma

Substanzen

5'-methylthioadenosine phosphorylaseBiomarkers, TumorCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16Purine-Nucleoside Phosphorylase

Autor:innen und Institutionen

  • Vivian L. Smith Department of Neurosurgery, The University of Texas, Health Science Center at Houston, Houston, TX, United States.
  • Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico.
  • Laboratorio de Neuronutricion y Memoria, CuSur, Universidad de Guadalajara, Ciudad Guzmán, México.
  • Instituto Politécnico Nacional, Mexico City, Mexico.
  • Instituto de Neurobiología, Campus Universidad Nacional Autónoma de México-Juriquilla, Querétaro, México.
  • Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, United States.

ORCID-Profile: Antonio Dono, Yoshua Esquenazi

Förderung

  • NCI NIH HHS
  • NIH HHS
  • National Cancer Institute
  • National Institutes of Health

Zitieren

APA

Dono, A., Pichardo-Rojas, D., Mendoza Mora, L., Pichardo-Rojas, P. S., Marin-Castañeda, L. A., Carrillo, A., Coria Medrano, A., Esquenazi, Y., & Ballester, L. Y. (2025). MTAP immunohistochemistry as a surrogate marker of CDKN2A loss in brain tumors: A meta-analysis and literature review. Journal of Neuropathology & Experimental Neurology, 84(7), 600-610. https://doi.org/10.1093/jnen/nlaf033

Vancouver

Dono A, Pichardo-Rojas D, Mendoza Mora L, Pichardo-Rojas PS, Marin-Castañeda LA, Carrillo A, et al. MTAP immunohistochemistry as a surrogate marker of CDKN2A loss in brain tumors: A meta-analysis and literature review. Journal of Neuropathology & Experimental Neurology. 2025;84(7):600-610. doi:10.1093/jnen/nlaf033

BibTeX
@article{Dono2025,
  author = {Dono, Antonio and Pichardo-Rojas, Diego and Mendoza Mora, Leonardo and Pichardo-Rojas, Pavel S and Marin-Castañeda, Luis A and Carrillo, Abril and Coria Medrano, Adrian and Esquenazi, Yoshua and Ballester, Leomar Y},
  title = {MTAP immunohistochemistry as a surrogate marker of CDKN2A loss in brain tumors: A meta-analysis and literature review},
  journal = {Journal of Neuropathology & Experimental Neurology},
  year = {2025},
  volume = {84},
  number = {7},
  pages = {600--610},
  doi = {10.1093/jnen/nlaf033}
}
Kostenlos starten →